Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine in Septic Shock
NCT05778838Phase 2Completed
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of midodrine in septic shock (2 arms). Primary endpoint: Mortality rates at 30 days. Started Nov 2022; status: completed.
02
Drugs
midodrine
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT05778838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05778838.